Several predictions and experimental approaches have defined a novel miR-31 target gene, MAP3K14 (also called NIK), which is a persistent NF-κB activator in various malignancies, including B cell lymphoma (Pham et al., 2011), multiple myeloma (Annunziata et al., 2007), breast cancer (Yamamoto et al., 2010), pancreatic cancer (Nishina et al., 2009), and ATL (Saitoh et al., 2008). Here, NFKB1 is linked to breast carcinoma.